Travere Therapeutics Q3'26 Results Set for November 2
The company is scheduled to report after the market closes. EPS is estimated at $(0.10).
Related stories
Prologis Reports Shares Outstanding Under Takeover Code Rule
Prologis said 950,515,926 common shares were issued and outstanding at the close of business on October 29, 2026, and that it held no shares in treasury.
H impact | EQUITY | Oct 30, 2026, 03:03 PM UTC
FedEx Freight Shares Surge 14% After Quarterly Beat and Strong Profit Outlook
Shares rose 14% in early trading Friday after FedEx Freight forecast fourth-quarter profit above analyst estimates. Analysts backed the trucking firm's 2027 growth expectations.
M impact | EQUITY | Oct 30, 2026, 03:02 PM UTC
Thermo Fisher Scientific Reports Third-Quarter Revenue of $12.14 Billion
Third-quarter 2026 revenue rose 9.1% year over year to $12.14 billion. Net income increased 6.5% to $1.72 billion, diluted EPS rose 8.7% to $4.64, and organic revenue growth was 6%
H impact | EQUITY | Oct 30, 2026, 03:01 PM UTC
HSBC Holdings Files Schedule 13G for New America Acquisition
HSBC Holdings filed a Schedule 13G concerning New America Acquisition. The filing date is listed as October 30, but the year is incomplete.
M impact | EQUITY | Oct 30, 2026, 03:00 PM UTC
US session market picture: S&P 500 -1.32%, Nasdaq 100 -2.69%; EUR/USD -0.18%, WTI +2.23%, WBD leads volume
US session market picture. US index futures: S and P futures is down 1.32 percent, Nasdaq futures is down 2.69 percent, Dow futures is down 0.49 percent and Russell futures is down
M impact | EQUITY | Oct 30, 2026, 03:00 PM UTC
AstraZeneca Launches $1.5 Billion Cost-Savings Program
AstraZeneca said it is launching the program to free up resources for investment in its drug pipeline.
M impact | EQUITY | Oct 30, 2026, 02:58 PM UTC